Show simple item record

dc.contributor.authorBarceló Bennasar, Antònia
dc.contributor.authorPiérola, Javier
dc.contributor.authorEsquinas López, Cristina
dc.contributor.authorPeña, Mónica de la
dc.contributor.authorArqué, Meritxell
dc.contributor.authorAlonso-Fernández, Alberto
dc.contributor.authorBauçà, Josep Miquel
dc.contributor.authorRobles, Juan
dc.contributor.authorBarceló, Bernardino
dc.contributor.authorBarbé Illa, Ferran
dc.date.accessioned2016-02-16T09:07:47Z
dc.date.available2016-02-16T09:07:47Z
dc.date.issued2014
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10459.1/55720
dc.description.abstractMethods: We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls. The occurrence of the MS was analyzed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) clinical criteria. Measurements of plasma renin activity (PRA), aldosterone, aldosterone:PRA ratio, creatinine, glucose, triglycerides, cholesterol and HDL cholesterol were obtained at baseline and after CPAP treatment. Results: Aldosterone levels were associated with the severity of OSAHS and higher than controls (p = 0.046). Significant differences in aldosterone levels were detected between OSAHS patients with and without MS (p = 0.041). A significant reduction was observed in the aldosterone levels in patients under CPAP treatment (p = 0.012). Conclusion: This study shows that aldosterone levels are elevated in OSAHS in comparison to controls, and that CPAP therapy reduces aldosterone levels. It also shows that aldosterone levels are associated with the presence of metabolic syndrome, suggesting that aldosterone excess might predispose or aggravate the metabolic and cardiovascular complications of OSAHS. Trial registration: The study is not a randomized controlled trial and was not registered.ca_ES
dc.language.isoengca_ES
dc.publisherPublic Library of Scienceca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1371/journal.pone.0084362ca_ES
dc.relation.ispartofPlos One, 2014, vol. 9, núm. 1, e84362ca_ES
dc.rightscc-by, (c) Barceló et al., 2014ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleRelationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatmentca_ES
dc.typearticleca_ES
dc.identifier.idgrec021268
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0084362


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Barceló et al., 2014
Except where otherwise noted, this item's license is described as cc-by, (c) Barceló et al., 2014